Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Biotecnología

Dr. Tara  Rheault M.P.H., Ph.D.

Senior Vice President of R&D

Mr. Christopher  Martin

Senior Vice President of Commercial

Ms. Nina  Church

Executive Director of Global Clinical Devel.

Dr. David S. Zaccardelli

Pres, Chief Executive Officer & Executive Director

Mr. Mark W. Hahn

Chief Financial Officer

Dr. Kathleen A. Rickard

Chief Medical Officer

Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA

Gen. Counsel

Ms. Victoria  Stewart

Director of Communications

Mr. Matthew  Casbon

Vice President of Sales, Marketing & Training

Ms. Ostra  Jewell

Senior Vice President of HR

Dr. Peter  Spargo

Senior Vice President of Chemistry Manufacturing & Controls

Nombre	Capitalización
hVIVO plc	0M
VistaGen Therapeutics, Inc.	0M
BioVaxys Technology Corp.	0M
MedMira Inc.	0M
Regenicin, Inc.	0M
Vascular Biogenics Ltd.	0M
CorMedix Inc.	0M
Wave Life Sciences Ltd.	0M
Immuron Limited	0M
Aptevo Therapeutics Inc.	0M

Verona Pharma plc

Verona Pharma plc Lista de competidores

Principales competidores